Pre-filled Syringe Version of GSK’s Shingles Vaccine Approved by FDA
On July 17, 2025, officials at the U.S. Food and Drug Administration (FDA) granted a license to GSK plc (formerly GlaxoSmithKline) to distribute a pre-filled syringe version of Shingrix (Zoster Vaccine Recombinant Adjuvanted) vaccine to control outbreaks of shingles (herpes zoster) in adults. The pre-filled syringe version of Shingrix was approved for use by adults […]
Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia
In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]
Appellate Court Tosses Out 1,200 Shingles Vaccine Injury Lawsuits Against Merck
The Third Circuit U.S. Court of Appeals dismissed approximately 1,200 lawsuits filed against Merck & Co. over its shingles vaccine, Zostavax. The Appellate Court upheld a U.S. District Court ruling that threw out the lawsuits for failing to abide by a court order requiring them to provide clinical test results.1 Zostavax, the first shingles vaccine […]